Target Validation Information
TTD ID	T67894
Target Name	Toll-like receptor 3 (TLR3)
Type of Target	Clinical trial
Action against Disease Model	BCG65-E7	Drug Info	Target of vaccines. Utilizing the E7-expressing murine t uMor cell line, TC-1, as a model of cervical carcinoma, an immunotherapy based on the administration of an adjuvant-freefusion protein comprised of Mycobacteri uM bovis BCG Hsp65 linked to HPV16 E7 (HspE7) has been developed. Initial in vitro analyses indicate that immunization with HspE7 results in the induction of atype 1 immune response based on the pattern of secreted cytokines and the presence of cytolytic activity following antigenic recall.	[1]
References
REF 1	Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol. 2000 Aug;121(2):216-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.